These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 19714737)

  • 1. Sample-size calculations for multi-group comparison in population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    Pharm Stat; 2010; 9(4):255-68. PubMed ID: 19714737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size calculations based on generalized estimating equations for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L; Graham G
    J Biopharm Stat; 2006; 16(2):135-50. PubMed ID: 16584063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2008; 18(6):1212-27. PubMed ID: 18991118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size/power calculations for population pharmacodynamic experiments involving repeated-count measurements.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2010 Sep; 20(5):1026-42. PubMed ID: 20721789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model.
    Steimer JL; Mallet A; Golmard JL; Boisvieux JF
    Drug Metab Rev; 1984; 15(1-2):265-92. PubMed ID: 6745083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On design considerations and randomization-based inference for community intervention trials.
    Gail MH; Mark SD; Carroll RJ; Green SB; Pee D
    Stat Med; 1996 Jun; 15(11):1069-92. PubMed ID: 8804140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models.
    Nguyen TT; Bazzoli C; Mentré F
    Stat Med; 2012 May; 31(11-12):1043-58. PubMed ID: 21965170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies.
    Foo LK; McGree J; Duffull S
    Pharm Stat; 2012; 11(4):325-33. PubMed ID: 22411749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample size/power calculations for repeated ordinal measurements in population pharmacodynamic experiments.
    Ogungbenro K; Aarons L
    J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):67-83. PubMed ID: 19967433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
    van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2009; 19(1):174-89. PubMed ID: 19127474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sampling strategies for occupational exposure assessment under generalized linear model.
    Chen CC; Chuang CL; Wu KY; Chan CC
    Ann Occup Hyg; 2009 Jul; 53(5):509-21. PubMed ID: 19460758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal design of pharmacokinetic studies.
    Aarons L; Ogungbenro K
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):250-5. PubMed ID: 20102362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covariate detection in population pharmacokinetics using partially linear mixed effects models.
    Bonate PL
    Pharm Res; 2005 Apr; 22(4):541-9. PubMed ID: 15846461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic investigation of actinomycin-D in children and young adults.
    Mondick JT; Gibiansky L; Gastonguay MR; Skolnik JM; Cole M; Veal GJ; Boddy AV; Adamson PC; Barrett JS
    J Clin Pharmacol; 2008 Jan; 48(1):35-42. PubMed ID: 18094218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
    Shen M; Schilder RJ; Obasaju C; Gallo JM
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration.
    Salinger DH; Vicini P; Blough DK; O'Donnell PV; Pawlikowski MA; McCune JS
    J Clin Pharmacol; 2010 Nov; 50(11):1292-300. PubMed ID: 20075185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of sample size on the performance of multiple-model pharmacokinetic simulations.
    Tam VH; Kabbara S; Yeh RF; Leary RH
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3950-2. PubMed ID: 16954312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.